Rejuran Skinbooster 3+3: Navigating Regulatory and Market Access Status

Rejuran Skinbooster 3+3 is a polynucleotide-based product developed by Pharma Research, a South Korean pharmaceutical company. It is categorized within the biostimulator and skinbooster segment, designed for professional aesthetic applications. This specific formulation is distinguished by its concentration and intended uses within aesthetic protocols. Professionals sourcing this product must prioritize understanding its legal standing in various international markets.

The regulatory landscape for aesthetic injectables varies significantly across regions. For Rejuran Skinbooster 3+3, as a product originating from South Korea, several key certifications are typically relevant:

• KFDA (Korean Ministry of Food and Drug Safety) Approval: As a domestic product, Rejuran formulations generally hold KFDA approval as medical devices within South Korea. This is a foundational regulatory baseline for products from Pharma Research.
• CE Mark Certification: For market access within the European Union (EU) and other regions recognizing the CE Mark, Rejuran Skinbooster 3+3 is typically designated as a Class III medical device. This certification signifies compliance with EU safety, health, and environmental protection requirements. Specific CE status for the '3+3' variant should be verified through supplier documentation.
• FDA (U.S. Food and Drug Administration) Status: Generally, South Korean polynucleotide skinboosters do not hold full FDA approval for direct aesthetic indications in the United States. Professionals in the US market must adhere to specific import regulations for medical devices, which may classify such products as investigational or non-approved for direct commercial sale. [VERIFY: specific FDA classification or import allowances for Rejuran Skinbooster 3+3].
• GMP & ISO Certifications: Manufacturing facilities for products like Rejuran are typically certified for Good Manufacturing Practices (GMP) and ISO standards (e.g., ISO 13485 for medical devices). These certifications ensure consistent quality control and adherence to international manufacturing standards, regardless of specific product approval status.

The presence of a valid CE Mark is paramount for legally importing and distributing Rejuran Skinbooster 3+3 within the European Union. Clinics in EU member states and the UK should ensure their suppliers provide evidence of this certification. Post-Brexit, the UK largely aligns with CE Mark requirements, though specific UKCA marking may become relevant for some medical devices in the future. Professionals should also be aware of national variations in medical device registration and professional use guidelines within these territories.

Access to Rejuran Skinbooster 3+3 in regions like the Gulf Cooperation Council (GCC) countries, Latin America (LATAM), and the broader Asia-Pacific (APAC) market often depends on local health authority registrations. For instance, countries in the GCC may require registration with bodies like the SFDA (Saudi Food and Drug Authority) or MOH (Ministry of Health) in UAE. Similarly, LATAM countries have their own regulatory bodies (e.g., ANVISA in Brazil, COFEPRIS in Mexico). In APAC, while KFDA is foundational, individual country approvals (e.g., HSA in Singapore, TGA in Australia) are necessary for local distribution. This fragmented regulatory environment emphasizes the need for comprehensive due diligence from professional buyers. Products like Lapuroon Aurora Super and AMI Eyes also navigate similar regional registration requirements.

The global nature of aesthetic product supply chains, including for Rejuran Skinbooster 3+3, can introduce complexities such as parallel imports. While sometimes legal, parallel imported goods may lack consistent regulatory oversight or traceability in new markets. Professionals must exercise caution to ensure they source original, authentic products. Unscrupulous suppliers might offer products without proper documentation or from unauthorized channels, impacting product integrity and patient safety. For more insights on navigating complex regulatory environments, refer to our article on Lipo Lab V-Line regulatory status.

For professionals, understanding the wholesale pricing and volume tiers for Rejuran Skinbooster 3+3 is essential for clinic economics. Illustratively, a unit may be priced around $197.0, with volume discounts typically available. These often follow structures such as:

These tiers allow clinics to optimize their procurement costs based on anticipated demand. Verifying these details with your supplier is always recommended, alongside requesting the necessary regulatory documentation.